A Relative Bioavailability Study of LY3454738 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 12, 2024

Primary Completion Date

May 2, 2024

Study Completion Date

May 2, 2024

Conditions

Healthy

Interventions

DRUG

LY3454738

Administered subcutaneously (SC)

Trial Locations (1)

ICON Early Phase Services, San Antonio

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT06173895 - A Relative Bioavailability Study of LY3454738 in Healthy Participants | Biotech Hunter | Biotech Hunter